Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood–brain barrier (BBB). A recent work delineates a biophysical method for BBB p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jonathan G. Pol, Manuela Lizarralde-Guerrero, Andrea Checcoli, Guido Kroemer
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	OncoImmunology
Subjects:	Blood-brain barrier cancer immunotherapy doxorubicin immune checkpoint inhibitor ultrasounds
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2385124
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of blood-tumor barrier permeability and doxorubicin delivery in rat brain tumor models using additional focused ultrasound stimulation
by: Hyo Jin Choi, et al.
Published: (2025-02-01)

A Review: Neurotoxicity of Doxorubicin
by: Hanan Saadon, et al.
Published: (2025-06-01)

Potentiating Effect of Nitric Oxide Donor on Antitumor Activity of Doxorubicin in Glioblastoma-Bearing Rats
by: A. I. Alekseeva, et al.
Published: (2020-05-01)

Doxorubicin enhanced the antitumor efficacy of sonodynamic therapy with photosensitizer photolon in an <i>in vivo</i> experiment
by: D. A. Tzerkovsky, et al.
Published: (2024-12-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01)

High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy
by: Lucillia Bezu, et al.
Published: (2024-12-01)

Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death
by: Peng Liu, et al.
Published: (2024-12-01)

Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue
by: Liwei Zhao, et al.
Published: (2025-12-01)

The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells
by: Annalisa Carretta, et al.
Published: (2024-09-01)

Trial watch: Toll-like receptor ligands in cancer therapy
by: Julie Le Naour, et al.
Published: (2023-12-01)

Dynamics of pathological changes of myocardial structures of rats under administration of doxorubicin
by: А. G. Rodinskij, et al.
Published: (2015-04-01)

Histopathological Evaluation of Erythropoietin's Protective Effect Against Doxorubicin-Induced Hepatotoxicity
by: Zeena Jasim Saddam, et al.
Published: (2025-05-01)

Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al.

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
by: JIA Xiaorong, et al.
Published: (2024-05-01)

Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin
by: Fouad Zeidan Hamzah, et al.
Published: (2025-07-01)

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer
by: Atefeh Ghahremanloo, et al.
Published: (2025-03-01)

Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity
by: Emilia ANCA, et al.
Published: (2024-12-01)

Targeting the proliferation of glioblastoma cells and enhancement of doxorubicin and temozolomide cytotoxicity through inhibition of PFKFB4 and HMOX1 genes with siRNAs
by: Hamzeh J. Al-Ameer, et al.
Published: (2025-07-01)

Pathophysiology of Doxorubicin-Mediated Cardiotoxicity
by: Roberto Arrigoni, et al.
Published: (2025-04-01)

Role of Bee Propolis and Vitamin E in Attenuating Doxorubicin-induced Hepatic Toxicity in Rats
by: Hodhaifa Abdul Mohsin, et al.
Published: (2025-04-01)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01)

Bilateral Wilms Tumour: Is Neoadjuvant Doxorubicin Necessary?
by: Tristan Boam, et al.
Published: (2025-04-01)

Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk
by: Gustavo Cavinato Herrera, et al.
Published: (2025-09-01)

Microneedles loaded with PD-L1 inhibitor and doxorubicin GelMA hydrogel for melanoma immunochemotherapy
by: Muzhou Teng, et al.
Published: (2025-07-01)

Histopathological evaluation of the effects of thymoquinone and resveratrol on the liver in rats administered doxorubicin
by: Mehmet Burak Ates, et al.
Published: (2022-09-01)

The role of circRNAs in resistance to doxorubicin
by: Mahla Sanati, et al.
Published: (2024-11-01)

Stability study of oxaliplatin and doxorubicin for intraperitoneal administration with hyperthermia
by: V. Escudero-Ortiz, et al.
Published: (2014-05-01)

Immunotherapy against glioblastoma using backpack‐activated neutrophils
by: Tatsuya Fukuta, et al.
Published: (2025-01-01)

The correlation between the level of doxorubicin-induced cardiac damage and serum soluble Fas in an experimental rat model
by: Dogan Kose, et al.
Published: (2018-01-01)

Longitudinal Assessment of QT Apex in Tumor‐Bearing Dogs Receiving Doxorubicin Monotherapy
by: Keita Kitagawa, et al.
Published: (2025-07-01)

Combination of nanosomal form of doxorubicin, interferon alpha, and nitroglycerin in the threatment of 101.8 glioblastoma in Wistar rats
by: V. V. Kudelkina, et al.
Published: (2022-01-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

Double Encapsulation of Resveratrol and Doxorubicin in Composite Nanogel—An Opportunity to Reduce Cardio- and Neurotoxicity of Doxorubicin
by: Lyubomira Radeva, et al.
Published: (2024-10-01)

Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity
by: Jingjing Ding, et al.
Published: (2025-04-01)

Metabolic checkpoints in glioblastomas: targets for new therapies and non-invasive detection
by: Wenhao Li, et al.
Published: (2024-11-01)

Ameliorative effects of agomelatine against doxorubicin-induced hepatotoxicity
by: Hasan Basri Savas, et al.
Published: (2025-08-01)

Apelinergic System Affects Electrocardiographic Abnormalities Induced by Doxorubicin
by: Kasper Buczma, et al.
Published: (2025-01-01)

Doxorubicin induced reversible cardiomyopathy: A Case report
by: K Tamakuwala, et al.
Published: (2015-07-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)